Trial · NCT00181155
Intravenous Allopurinol in Heart Failure
NCT00181155, Phase 2, Completed, Johns Hopkins University; results first posted 2016-02-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravenous Allopurinol in Heart Failure. Trials, record NCT00181155. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00181155
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravenous Allopurinol in Heart Failure
- NCT number
- NCT00181155
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Congestive Heart Failure
- Interventions
- Allopurinol, Placebo
- First posted
- 2005-09-16
- Last updated
- 2017-05-30
- Results first posted
- 2016-02-09
- Limitations and caveats
- The limitations of the current study include the small placebo group sample size and the etiologic heterogeneity of the nonischemic cardiomyopathy group.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion | Onset of imaging acquisition. | Magnetic resonance spectroscopy (MRS) Measurement of Myocardial CK Flux Pre Intravenous Allopurinol Infusion |
| Primary | Myocardial CK Flux Post Intravenous Allopurinol Infusion. | acute (within 15 minutes of single infusion) | The mean rate of adenosine triphosphate (ATP) flux through the creatine kinase reaction in the heart. |
| Secondary | Cardiac PCr/ATP Pre Intravenous Infusion | Onset of image acquisition. | The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless. |
| Secondary | Cardiac PCr/ATP Post Intravenous Infusion | acute (within 15 minutes of single infusion) | The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion | Onset of imaging acquisition. | Data were analyzed for all participants who completed the MRS per protocol. | umol/g/sec | MEAN |
| SECONDARY | Cardiac PCr/ATP Pre Intravenous Infusion | Onset of image acquisition. | Data were analyzed for all participants who completed the MRS per protocol. | ratio | MEAN |
| PRIMARY | Myocardial CK Flux Post Intravenous Allopurinol Infusion. | acute (within 15 minutes of single infusion) | Data were analyzed for all participants who completed the MRS per protocol. | umol/g/sec | MEAN |
| SECONDARY | Cardiac PCr/ATP Post Intravenous Infusion | acute (within 15 minutes of single infusion) | Data were analyzed for all participants who completed the MRS per protocol. | ratio | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion | Baseline | 2.07 | Standard Deviation 1.27 | umol/g/sec | |
| Cardiac PCr/ATP Pre Intravenous Infusion | Baseline | 1.58 | Standard Deviation 0.41 | ratio | |
| Myocardial CK Flux Post Intravenous Allopurinol Infusion. | Intravenous Allopurinol | 2.87 | Standard Deviation 1.82 | umol/g/sec | |
| Cardiac PCr/ATP Post Intravenous Infusion | Intravenous Allopurinol | 1.75 | Standard Deviation 0.59 | ratio |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Allopurinol | 15 | |
| Overall Study | STARTED | Placebo | 3 | |
| Overall Study | COMPLETED | Allopurinol | 13 | |
| Overall Study | COMPLETED | Placebo | 3 | |
| Overall Study | NOT COMPLETED | Allopurinol | 2 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 - Intravenous Allopurinol | ||
| Total, all-cause mortality | Arm 2 - Placebo | ||
| Total, other adverse events | Arm 1 - Intravenous Allopurinol | 0 | 13 |
| Total, other adverse events | Arm 2 - Placebo | 0 | 3 |
| Total, serious adverse events | Arm 1 - Intravenous Allopurinol | 0 | 13 |
| Total, serious adverse events | Arm 2 - Placebo | 0 | 3 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22361399 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01HL061912 | Altered Energy Metabolism in Human Heart Failure | WEISS, ROBERT G | JOHNS HOPKINS UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 1999 to 2020 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Arm 1 - Intravenous Allopurinol vs Arm 2 - Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00181155
GET https://conductscience.org/api/trials/v1/NCT00181155/registered